注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Athersys Inc是一家生物技术公司。它致力于发现和开发候选治疗产品。它的MultiStem(invimestrocel)细胞疗法是一种异基因干细胞候选产品,是它的主要平台产品,目前处于临床开发的后期。多阶段细胞治疗包括重症监护适应症、神经系统疾病、炎症和免疫障碍、某些肺部疾病、心血管疾病和其他疾病的治疗。MultiStem细胞疗法是从成人骨髓中获得的人类干细胞制造的,这些细胞也可以从其他组织来源获得。它正在进行一项称为MASTERS-2的多阶段细胞疗法治疗缺血性中风的III期临床试验。它正在纳入一项关键的II/III期临床试验,评估多阶段细胞疗法对COVID-19诱导和其他病原体诱导的急性呼吸窘迫综合征(ARDS)患者的疗效。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
James G. Shook | 84 | 2000 | Scientific and Clinical Advisor |
Michael Simons | - | - | Scientific and Clinical Advisor |
Warren Sherman | 73 | - | Scientific and Clinical Advisor |
Marc Steven Penn | - | - | Scientific and Clinical Advisor |
Ira Mellman | - | - | Scientific and Clinical Advisor |
Robert F. Kushner | - | - | Scientific and Clinical Advisor |
Jerry Silver | - | - | Scientific and Clinical Advisor |
Gilbert Clincke | - | - | Scientific and Clinical Advisor |
Brian H. Annex | - | - | Scientific and Clinical Advisor |
F. Xavier Pi-Sunyer | - | - | Scientific and Clinical Advisor |
Larry Wechsler | - | - | Scientific and Clinical Advisor |
John Wagner | - | - | Scientific & Clinical Advisor |
Richard T. Maziarz | - | - | Scientific & Clinical Advisor |
Hillard M. Lazarus | - | - | Scientific & Clinical Advisor |
C. Thomas Caskey | 84 | 2000 | Scientific and Clinical Advisor |
Catherine Verfaillie | - | - | Scientific and Clinical Advisor |
David Hess | - | - | Scientific and Clinical Advisor |
Z. Kasey Rosado | 50 | 2022 | Interim CFO & Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核